Antibodies against the major cysteine proteinase (cruzipain) from Trypanosoma cruzi were detected in human sera obtained from patients with chronic Chagas' disease. Not only the intact 60-kDa enzyme but also its 25-kDa self-proteolysis fragment are antigenic in vivo. Although T. cruzi antigens 13 and 36 also reacted with the apparently monospecific antiproteinase serum, the antigenicity of cruzipain to human patients is genuine, since its reactivity was not modified by the adsorption of human sera with the recombinant proteins 13 and 36.
ern blots (immunoblots) of purified enzyme, the C-terminal domain of the proteinase, Tul 2 epimastigote protein extracts, or recombinant proteins were processed as previously described (3) , except for the use of minigels (12% acrylamide) and of nonfat milk as a blocking agent instead of bovine serum albumin (6) ; or (ii) dot blots of recombinant proteins with ,-galactosidase, corresponding to different T. cruzi cloned antigens (8, 9) , were carried out. The fusion proteins were induced (8) , and the nitrocellulose filters were then processed (6), as previously described.
Figure la shows that Western blots of the purified enzyme reacted with sera from human patients with chronic Chagas' disease (chronic-patient sera). Of 13 different sera from patients with confirmed Chagas' disease, 11 reacted with cruzipain, giving an identical pattern (results obtained with two positive serum samples, as well as with the antiproteinase serum, are shown in Fig. la ). Of 12 sera from patients with acute cases, only 1 gave a weak positive reaction. Normal sera, or sera from patients with kala-azar, did not react at all. Table 1 summarizes the results, including the reactivities of the sera used against other T. cruzi antigens. All sera, whether positive or negative for cruzipain, reacted with at least two, and usually more, of the cloned antigens (Table 1) . It is noteworthy that immunoreactivity was shown not only for the intact 60-kDa cruzipain molecule but also for the 30-to 35-kDa fragments (some of them corresponding to the central domain and some to the C-terminal domain), which very frequently copurify with the native enzyme (5) . Moreover, the approximately 25-kDa self-proteolysis fragment, corresponding to the C-terminal domain of cruzipain (7), was also reactive, both with the antiproteinase serum and with chronic-patient sera (Fig. 2) . The specificity of the antiproteinase serum is shown by its lack of reaction with other parasite proteins present in total extracts of epimastigotes of the Tul 2 stock, which is at variance with the complex pattern presented by the human sera (Fig. lb) .
Our initial attempts to clone the gene coding for the enzyme by using a polyclonal, monospecific antiserum against the purified enzyme (3) and a genomic expression library of T. cruzi led to the isolation of a number of clones which proved, after partial sequencing, to be identical with clone 13, which encodes a different, 85-kDa parasite antigen (9) . This fact suggested an apparent immunological crossreactivity between cruzipain and other parasite antigens. Since the positive results shown in Fig. 1 might therefore be due to this cross-reactivity, we decided to test the antipro- speculation. At least some of these epitopes are located in the protein moiety, since the nonglycosylated C-terminal extension expressed in pGEX strongly reacted with both the rabbit antiserum and the chronic-patient sera (shown for H2 in Fig. 2) . The apparent molecular mass of the fusion protein, about 40 kDa, fits in well with the value obtained by adding the 142 amino acids of the C-terminal fragment (15 kDa) to the 25-kDa glutathione S-transferase. We cannot discard at present the possibility that other recognized epitopes include the carbohydrate moiety. teinase serum against antigens 1, 2, 7, 13, 30, and 36, using the corresponding recombinant proteins expressed in Escherichia coli systems, by the dot-blot technique (8) . Despite the fact that the antiserum reacted only with cruzipain in Western blots of both epimastigote and trypomastigote extracts (3) (Fig. lb) , it also reacted strongly with the fusion protein corresponding to clone 13 and, to a lesser extent, with that corresponding to clone 36 (not shown). All other antigens were negative. To demonstrate that the immunoreactivity of cruzipain was genuine, both the antiproteinase serum and five of the positive human serum samples were adsorbed with the recombinant proteins corresponding to clones 13 and 36. Although reactivity against these antigens was undetectable after adsorption, all sera were still reactive with the enzyme in Western blots. Results for human serum H2 are shown in Fig. 2 ; identical patterns were obtained before and after adsorption with all other sera tested. Removal of reactivity against the recombinant protein of clone 13 expressed in pGEX by adsorption is shown in Fig. 2 . Controls with either phage lambda gtll without insert or pGEX expressing the unrelated antigen number 30 were negative with all sera tested (not shown). The nature of the epitopes recognized by the sera on the cruzipain molecule, which is a glycoprotein, is at present only a matter of Anti -Pr. The immunoreactivity of cruzipain is genuine and not due to cross-reactivity with other parasite antigens. Reactivity of antiproteinase serum (Anti-Pr), anti-clone 13 protein (anti 13) , and H2 human chronic serum before (-) or after (+) absorption with the fusion proteins expressed in pGEX of clone 13. Proteins used for Western blotting were purified proteinase (A), a preparation highly enriched in the self-proteolysis 25-kDa fragment (B), and fusion protein of clone 13 expressed in pGEX (C). D, fusion protein of the C-terminal domain of cruzipain expressed in pGEX. Approximately
The reasons for the observed cross-reactivity are not clear. The possibility that the purified cruzipain utilized for the immunization of rabbits contained traces of the highly antigenic clone 13 and 36 proteins, and thus that the apparent cross-reactivity was the result of the simultaneous presence of different specific antibodies, may be ruled out, since (i) neither the clone 13 protein nor its mRNA has been detected in epimastigotes, which are the source for cruzipain purification (8) and (ii) no protein of 85 kDa, the size of antigen 13, was detected with the antiproteinase serum in Western blots of total parasite extracts (Fig. lb) (3) . Two of the chronicpatient serum samples positive with cruzipain were negative with the clone 13 protein, and four serum samples from patients with acute cases that were positive with clone 13 were negative with cruzipain. Also, six serum samples positive with cruzipain were negative with the clone 36 protein (Table 1 ). Since the sequences of cruzipain (1) and of part of the clone 13 and 36 proteins, specifically the amino acid repeats (9) , are known, a search for homologies in the primary structures was conducted. The sequence SGE was found both in one of the variants of the clone 13 repeat (9) and in positions 96 to 98 of cruzipain (1) . The sequences LPQXEXQ and LPT are present in the repeat of clone 36 and in amino acids 121 to 127 and 261 to 263, respectively, of cruzipain (1). These short amino acid sequences might be relevant, since short cross-reacting epitopes have been recently reported for Plasmodium falciparum (10) .
The present results fit in well with the recent demonstration that a T. cruzi antigen, GP 57/51 (13), which is recognized by most sera from chronic patients, has an N terminus characteristic of a cysteine proteinase, being probably identical with, or very closely related to, cruzipain (11) . In this context, the strong reactivity shown by the 25-kDa selfproteolysis fragment may be quite relevant, since the same authors had earlier described another antigen, GP25 (12) , which was later considered to be a degradation product of GP 57/51 (13) . Since the whole gene has been cloned and sequenced (1) and thus both the whole enzyme and selected fragments thereof can be produced in E. coli in large amounts (shown for the C-terminal domain in Fig. 2) , we are at present evaluating the possible use of cruzipain or its C-terminal domain as a diagnostic reagent for chronic Chagas' disease.
